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ABSTRACT
Malignant mesothelioma originates from mesothelial cells and is a cancer type 
that aggressively invades into the surrounding tissue, has poor prognosis and no 
effective treatment. Gremlin-1 is a cysteine knot protein that functions by inhibiting 
BMP-pathway activity during development. BMP-independent functions have also 
been described for gremlin-1. We have previously shown high gremlin-1 expression 
in mesothelioma tumor tissue. Here, we investigated the functions of gremlin-1 in 
mesothelioma cell migration and invasive growth. Gremlin-1 promoted mesothelioma 
cell sprouting and invasion into three dimensional collagen and Matrigel matrices. 
The expression level of gremlin-1 was linked to changes in the expression of SNAI2, 
integrins, matrix metalloproteinases (MMP) and TGF-β family signaling - all previously 
associated with a mesenchymal invasive phenotype. Small molecule inhibitors of MMPs 
completely blocked mesothelioma cell invasive growth. In addition, inhibitors of TGF-β 
receptors significantly reduced invasive growth. This was associated with reduced 
expression of MMP2 but not SNAI2, indicating that gremlin-1 has both TGF-β pathway 
dependent and independent mechanisms of action. Results of in vivo mesothelioma 
xenograft experiments indicated that gremlin-1 overexpressing tumors were more 
vascular and had a tendency to send metastases. This suggests that by inducing a 
mesenchymal invasive cell phenotype together with enhanced tumor vascularization, 
gremlin-1 drives mesothelioma invasion and metastasis. These data identify gremlin-1 
as a potential therapeutic target in mesothelioma.
INTRODUCTION
Malignant mesothelioma is an aggressive cancer 
that develops from the mesothelial cells of serosal 
membranes [1]. Most often mesothelioma originates from 
the pleural lining of the lung. Occupational or incidental 
exposure to asbestos fibers is a known causative factor 
in mesothelioma and the latency period from exposure 
to tumor incidence can be long [2]. Mesothelioma 
prognosis is poor, survival time being usually only 10–14 
months after diagnosis [3]. There are three histological 
subtypes of mesothelioma. Epithelioid mesothelioma is 
the most common type with prominent papillotubular 
structures seen in histological micrographs. Sarcomatoid 
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mesothelioma is characterized by spindled cells mimicking 
fibrosarcoma. Biphasic mesothelioma has areas of both 
epithelioid and sarcomatoid histology. Mesothelioma 
shows aggressive local growth and invasion into the chest 
wall, diaphragm or contralateral lymph nodes [1]. Distant 
metastases are occationally detected. Mesothelioma is 
highly resistant to conventional cancer therapies.
Invasive processes are regulated by the tumor 
microenvironment, where the extracellular matrix 
molecules and secreted growth factors contribute to the 
transition of tumor cells towards a migratory and invasive 
phenotype. It is noteworthy that tumor cell invasion and 
metastases may be an unrelated process to tumor cell 
proliferation and occur already at early stages of tumor 
development [4]. Therefore, it is essential to identify 
molecules that potentiate mesothelioma invasion and 
dissemination. Gremlin-1 is a member of the DAN family 
of BMP antagonists, which inhibits mainly the activity of 
BMP-2 and -4 by direct binding to the growth factor [5]. 
Gremlin-1 plays essential roles especially during kidney, 
lung and bone development [6]. It has been identified as 
a niche factor contributing to stem cell proliferation by 
blocking BMP signaling [7]. BMP-independent functions, 
such as modulation of VEGFR2-dependent induction of 
angiogenesis and inhibition of macrophage migration 
inhibitory factor (MIF), have also been described for 
gremlin-1 [8, 9]. Recently, gremlin-1 expression has been 
associated with tumorigenesis. Gremlin-1 was found to 
be expressed by cancer-associated stromal cells in the 
tumor tissues and this way thought to contribute to a 
microenvironment regulated tumor growth and invasion 
[10]. We and others have found gremlin-1 to be expressed 
by the tumor cells [11]. Our previous studies suggest that 
mesothelioma cells secrete high amounts of gremlin-1, 
which is targeted into fibrillin-2 rich microfibrils in the 
mesothelioma tumor tissue [12].
To better understand the functions of gremlin-1 in 
mesothelioma we assessed mesothelioma cell migration 
and invasion in vitro and in vivo. Mesothelioma invasion 
into 3D collagen matrix was dependent on gremlin-1 
expression. Gremlin-1 associated with the expression 
of the EMT transcription factor SNAI2, modulation of 
proteolytic enzyme expression and increase in TGF-β 
pathway activity. Data from in vivo tumor xenograft 
experiments indicated a vascular phenotype and a 
tendency to send metastases in gremlin-1 expressing 
tumors. These results indicate that gremlin-1 drives 
invasion and dissemination in mesothelioma.
RESULTS
Gremlin-1 drives invasive growth of 
mesothelioma cells in 3D culture
Since mesothelioma tumors are highly invasive 
locally, we analyzed whether gremlin-1 regulates 
invasive growth of mesothelioma cells. H2052 and JL-1 
mesothelioma cell lines, which express higher mRNA 
levels of gremlin-1 than non-tumorigenic and non-invasive 
Met5A control cells (Figure 1A), showed invasive 
sprouting when tumor cell spheroids were imbedded into 
3D collagen matrix (Figure 1B). H28 and 211H cells 
with undetectable or low gremlin-1 expression were not 
invasive under similar conditions. Gremlin-1 expression 
was silenced in H2052 cells using two different siRNAs. 
Both siRNAs reduced gremlin-1 mRNA expression 
significantly, siRNA3 being more effective with 95% 
reduction of expression (Figure 1C). Control siRNA 
treated cells embedded into 3D Matrigel were able to form 
irregular shaped colonies and invade and sprout through 
the surrounding matrix (Figure 1D). Gremlin-1 silencing 
efficiently inhibited both Matrigel and collagen invasion 
of H2052 cells (Figure 1D, 1E). Similar reduction in 
collagen invasion was noted in gremlin-1 silenced JL-1 
cells, which were followed up to 72 h after embedding of 
cell spheroids into 3D collagen (Figure 1E). In addition, 
gremlin-1 silencing resulted in downregulation of the 
expression of the EMT transcription factor SNAI2 (Figure 
1F), similar to what we have reported previously in H2052 
cells [12].
Primary mesothelioma cells isolated from pleural 
effusions of mesothelioma patients express high mRNA 
levels of gremlin-1 [12]. We noticed that primary 
cells initially grew slowly, but when passaged more 
than 10 times the growth was gradually increased (not 
shown). JP4 early passage cells, but not late passage 
cells, were able to sprout and invade into 3D Matrigel 
(Figure 2A). This change in 3D phenotype was associated 
with downregulation of GREM1 mRNA expression 
(Figure 2B). In late passage JP4 and JP5 cells there was 
a concomitant decrease in the expression level of SNAI2, 
which is consistent with our previous results linking 
gremlin-1 to a mesenchymal mesothelioma phenotype. 
When gremlin-1 was re-expressed in JP4 and JP5 late 
passage cells using lentiviral expression vectors, there was 
a gain of invasive growth and sprouting into 3D Matrigel 
(Figure 2C, Supplementary Figure 1).
Early passage primary mesothelioma cells showed 
robust invasive sprouting into 3D collagen matrix already 
at 24 hour time point (Figure 2D). Furthermore, late 
passage JP5 cells transduced to re-express gremlin-1 
(JP5/grem1) were also invasive in 3D collagen, while JP5 
control cells (JP5/ctrl) were not (Figure 2E). The results 
indicate that the ability of mesothelioma cells to invade 
into Matrigel or collagen matrices is linked to gremlin-1 
expression. Gremlin-1 re-expression was associated with 
increased levels of SNAI2 and decreased levels of CDH1 
mRNA expression (Figure 2F). E-cadherin protein levels 
were 5-fold higher in JP5/ctrl cells, indicating a significant 
decrease by gremlin-1 expression (Figure 2G). In addition, 
the formation of actin stress fibers was observed in JP5/
grem1 cells (Figure 2H). This suggests that gremlin-1 
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regulates the invasive growth of mesothelioma cells by 
driving a mesenchymal phenotype.
Mesothelioma cell adhesion and migration is 
regulated by gremlin-1
We observed that silencing or overexpression of 
gremlin-1 in mesothelioma cells affected the adhesion 
of cells in 2D cultures. Therefore, we used a commercial 
PCR array to analyze the mRNA expression levels of 
extracellular matrix and adhesion molecules in gremlin-1 
silenced H2052 cells (see Methods). Gremlin-1 silencing 
reduced the expression of several mesenchymal matrix 
proteins including FN1, SPARC and TNC (Supplementary 
Figure 2). In addition, the expression of integrin subunits 
was downregulated. ITGAV, collagen integrin alpha 
Figure 1: Gremlin-1 regulates 3D invasion of mesothelioma cell lines. (A) H2052, JL-1 and 211H mesothelioma cells were 
analyzed for GREM1 expression by quantitative RT-PCR. The level was normalized to the expression levels of TATA-binding protein and 
is expressed relative to the expression level in Met5A (immortalized, non-tumorigenic mesothelial cells), which was set to 1. The error 
bars represent SD (n = 3). (B) Invasive growth of Met5A control cells and mesothelioma cell lines was analyzed in three-dimensional (3D) 
collagen 1 matrix. Cells were embedded into the matrix as spheroids and followed up to 72 hours. (C) GREM1 expression was analyzed in 
control siRNA (ctrl_siRNA) and gremlin-1 siRNA (grem1_siRNA) transfected cells 72 hours after transfection. The results are expressed 
relative to the expression level in ctrl_siRNA transfected cells, which was set to 1. The error bars represent SD (n = 3). (D) Invasive growth 
of gremlin-1 silenced H2052 cells was analyzed in 3D Matrigel or collagen 1 matrix. (E) Invasive growth of gremlin-1 silenced JL-1 cells 
was analyzed in 3D collagen 1 matrix. Images were taken at 72 hours. Graphs show quantification as relative spheroid surface area. The 
error bars represent SD (n = 3). *p < 0.05. (F) Relative expression of GREM1 and SNAI2 in control siRNA (ctrl_siRNA) and gremlin-1 
siRNA (grem1_siRNA) transfected cells 72 hours after transfection. The error bars represent SD (n = 3). *p < 0.05.
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Figure 2: Rescue of 3D invasive growth by gremlin-1 overexpression. (A) Early and late passage JP4 mesothelioma cells 
were embedded into 3D Matrigel and followed for 72 hours. (B) Expression of GREM1 and SNAI2 in early and late passage JP4 and JP5 
mesothelioma cells. The results are expressed relative to the expression level in early passage JP4 cells, which was set to 1. A representative 
experiment is shown. (C) Late passage JP4 mesothelioma cells transduced to express gremlin-1 (JP4/grem1) or control cells (JP4/ctrl) 
were embedded into 3D Matrigel and followed for 72 hours. (D–E) Early passage JP3 and JP9 primary mesothelioma cells and JP5 
mesothelioma cells transduced to express gremlin-1 (JP5/grem1) or control cells (JP5/ctrl) were embedded into 3D collagen 1. Images were 
taken at 24 or 72 hours. Graphs shows quantification as relative spheroid surface area. The error bars represent SD (n = 3). *p < 0.05. (F) 
Expression of SNAI2 and CDH1/E-cadherin in JP5/ctrl and JP5/grem1 cells. The results are expressed relative to the expression level in 
JP5/ctrl cells, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (G) Cell conditioned media (normalized according to cell 
number) or cell lysates were analyzed by Western blotting using antibodies specific to gremlin-1, E-cadherin or β-tubulin (loading control). 
The molecular weight markers (kDa) are shown on the left. (H) JP5/ctrl and JP5/grem1 cells were stained for F-actin (red) and analyzed 
using immunofluorescence microscopy. Cell nuclei were counterstained with DAPI (blue).
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subunits ITGA1 and ITGA2 as well as ITGA4 were all 
significantly downregulated (Figure 3A). More detailed 
quantitative RT-PCR analyses confirmed that these 
integrin subunits were downregulated in gremlin-1 
silenced JL-1 and H2052 cells and upregulated in JP5/
grem1 cells (Figure 3B). The expression of the integrin 
beta subunit ITGB1 was not significantly altered.
Integrins play an essential role in cancer cell 
attachment and migration. Integrin αv subunit forms 
fibronectin binding heterodimers. Therefore cell 
attachment assays using fibronectin or collagen 1 were 
performed next. We observed significantly reduced 
binding of H2052 cells to fibronectin when gremlin-1 
was silenced (Figure 3C). However, integrin αv blocking 
antibody or the integrin inhibitor cilengitide (20 μM) were 
not able to reduce H2052 cell invasion into 3D collagen 
(not shown). H2052 cell adhesion to collagen 1 was also 
significantly reduced by gremlin-1 silencing, although 
to a lesser extent (Figure 3C). JP5/grem1 cells showed 
increased adhesion to collagen 1 as well as increased 
migration in a wound healing assay (Figure 3D–3E). 
In addition, JP5 cells/grem1 cells showed increased 
migration/invasion in a Transwell assay with 1% serum as 
a chemoattractant or using collagen 1 coating of the inserts 
(Figure 3F). Gremlin-1 silencing in JL-1 cells decreased 
migration/invasion through collagen 1 coated inserts. The 
results suggest that modulation of integrin expression and 
cell adhesion is linked to gremlin-1 induced change in 
mesothelioma cell phenotype.
MMP activity is crucial for gremlin-1 induced 
3D invasion
The PCR array revealed also downregulation of 
the expression of several matrix metalloproteinases in 
gremlin-1 silenced H2052 cells (Figure 4A). Especially 
MMP2, MMP9, and MMP16 expressions were significantly 
downregulated, MMP14 also showing a trend towards 
reduced expression. Relative expression of different MMPs 
varied to some extent in the cell lines; however, MMP14 
(MT1-MMP) was the most abundantly expressed MMP 
while MMP9 levels were low (Supplementary Figure 3). 
Quantitative RT-PCR analyses confirmed that several MMPs 
were downregulated in gremlin-1 silenced H2052 and JL-1 
cells. However, although MMP2 and MMP9 expressions 
were upregulated in JP5/grem1 cells, the expression of 
membrane type MMPs (MMP14 and MMP16) was not 
increased (Figure 4B). Gelatin zymography assay indicated 
that MMP-2 and MMP-9 proteins were downregulated in 
gremlin-1 silenced H2052 cells and that MMP-2 protein 
levels were upregulated in JP5/grem1 cell conditioned 
medium (Figure 4C). The invasive growth of H2052 and 
JP5/grem1 cells into 3D collagen matrix was blocked by 
broad spectrum MMP inhibitors (GM6001 and BB2516) 
confirming the role of MMPs in gremlin-1 induced invasive 
growth (Figure 4D–4E).
Activin-A and TGF-β expression is linked to 
gremlin-1 induced invasive growth
We and others have previously linked activin 
and TGF-β isoform expression to mesothelioma [13]. 
Reciprocal regulation of gremlin-1 and TGF-β pathway 
activity has also been reported [14, 15]. In addition, many 
TGF-β pathway genes were found to be downregulated 
in gremlin-1 silenced cells. Therefore, we analyzed the 
mRNA expression levels of INHBA (activin-A subunit), 
TGFB1 and TGFB2 in mesothelioma cells. Gremlin-1 
silencing significantly reduced TGFB2 and INHBA 
expression but did not alter TGFB1 expression in H2052 
cells (Figure 5A). In JL-1 cells gremlin-1 silencing 
reduced the expression of all isoforms, TGFB1 being the 
most downregulated gene. JP5/grem1 cells, on the other 
hand, expressed more TGFB2, suggesting a link between 
gremlin-1 and activin/TGF-β isoform expression.
The effects of gremlin-1 silencing on TGF-β and 
BMP-pathway activities were studied using promoter 
luciferase constructs (see Methods). BMP-pathway activity 
was increased and TGF-β-pathway activity decreased 
in H2052 cells upon gremlin-1 knockdown (Figure 5B). 
In JP5 cells gremlin-1 overexpression led to a dramatic 
decrease in BMP-pathway activity as expected. TGF-β-
pathway activity was increased. Secretion of active and 
latent forms of TGF-β into the cell culture medium were 
analyzed using reporter cells (see Methods). Silencing 
gremlin-1 in H2052 cells reduced and overexpression of 
gremlin-1 in JP5 cells increased the secretion of both active 
and total TGF-β (Figure 5C). This is in agreement with the 
promoter studies and is evidence of altered TGF-β/BMP 
signaling balance in mesothelioma cells.
We have previously shown that inhibition of activin 
activity using a soluble activin receptor 2B (sActR2B-Fc) 
reduces mesothelioma cell migration and invasive growth 
in 3D Matrigel matrix [16]. However, blocking activin 
activity with sActR2B-Fc or recombinant follistatin 
were alone not able to inhibit 3D collagen invasion of 
H2052 cells (Figure 5D). Inhibition of activin/TGF-β 
pathway receptors (ALK4, ALK5 and ALK-7) by small 
molecule inhibitors (SB431542 and SB505124) reduced 
3D collagen invasion of H2052 and JP5/grem1 cells 
(Figure 6A) suggesting a role for activin/TGF-β pathways 
in gremlin-1 induced invasive growth. In agreement, 
treatment of JL-1 and JP5/grem1 cells with SB431542 
for 2 days reduced the mRNA expression of TGF-β target 
gene PAI1 as well as MMP2 and ITGAV. However, SNAI2 
and MMP14 expressions were not reduced indicating also 
TGF-β pathway independent functions for gremlin-1.
Inhibition of BMP receptor pathway alone does 
not induce invasive growth
Gremlin-1 inhibits mainly the functions of BMP-2 
and -4 [5]. We analyzed in our cell systems the expression 
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Figure 3: Mesothelioma cell adhesion and migration is regulated by gremlin-1. (A) Extracellular matrix and adhesion molecule 
PCR array was used to analyze gene expression in control siRNA (ctrl_siRNA) or gremlin-1 siRNA (grem1_siRNA3) transfected H2052 
cells 3 days after transfection. The results are expressed relative to the expression level of ITGA1 in H2052 control siRNA transfected cells, 
which was set to 1. The error bars represent SD (n = 2). (B) Expression of integrin genes in gremlin-1 silenced (grem1_siRNA) H2052 or 
JL-1 cells and in JP5/grem1 cells. The results are expressed relative to each control (control siRNA transfected or JP5/ctrl), which was set to 
1. The error bars represent SD (n = 3). *p < 0.05. (C) Control siRNA (ctrl_siRNA) or gremlin-1 siRNA (grem1_siRNA3) transfected H2052 
cells were allowed to adhere to fibronectin or collagen 1 coated wells for 1 hour. (D) JP5/ctrl or JP5/grem1 cells were allowed to adhere 
to collagen 1 for 30 min. Quantification of cells with a spread/elongated morphology is shown. The error bars represent SD (n = 3). *p < 
0.05. (E) Cell migration was analyzed using a scratch-wound assay and monitored by 24-h live cell imaging. The results are presented as 
relative wound density. The error bars represent SD (n = 2). (F) Migration (1% serum as chemoattractant) or invasive migration (collagen 1 
coated Transwell inserts) of JP5/ctrl, JP5/grem1 and JL-1 cells transfected with control or gremlin-1 siRNA is shown. Migrated cells were 
fixed, stained and imaged 16 hours after seeding. Graphs represent quantification of relative migration. The error bars represent SD (n = 
3). *p < 0.05.
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of these two BMPs as well as the expression of type I 
(ACVR1/ALK2, BMPR1A/ALK3, BMPR1B/ALK6) 
and type II (BMPRII) receptors, which mediate BMP 
pathway signaling. BMP4 expression was increased in 
gremlin-1 silenced cells and decreased in JP5/grem1 cells 
as compared to the controls (Figure 7A). In JL-1 gremlin-1 
silenced cells BMP2 expression was instead decreased. 
ALK6 receptor expression was low or undetectable in 
mesothelioma cells (data not shown). ALK2 expression 
decreased in gremlin-1 silenced cells and increased in JP5/
Figure 4: MMP activity is crucial for gremlin-1 induced 3D collagen invasion. (A) Extracellular matrix and adhesion molecule 
PCR array was used to analyze gene expression in control siRNA (ctrl_siRNA) or gremlin-1 siRNA (grem1_siRNA3) transfected H2052 
cells 3 days after transfection. The results are expressed relative to the expression level of MMP9 in H2052 control siRNA transfected 
cells, which was set to 1. The error bars represent SD (n = 2). (B) Expression of MMP genes in gremlin-1 silenced (grem1_siRNA) H2052 
or JL-1 cells and in JP5/grem1 cells. The results are expressed relative to each control (control siRNA transfected or JP5/ctrl), which was 
set to 1. The error bars represent SD (n = 3). *p < 0.05. (C) Cell conditioned media (normalized to cell number) were analyzed by gelatin 
zymography. MMP-9 and MMP-2 (inactive, intermediate and active forms) in control sample (PMA treated HT1080 lysate) are shown 
on the left, molecular weight markers (kDa) on the right. Quantification of MMP-2 level is indicated from a representative experiment. 
(D) Invasive growth of H2052 and JP5/grem1 cells was analyzed in 3D collagen 1 matrix in the presence of DMSO or MMP inhibitors 
(GM6001 or BB2516 at 10 μM concentration). Graphs show quantification as relative spheroid surface area. The error bars represent SD 
(n = 3). *p < 0.05. (E) Images from H2052 cells treated with DMSO or MMP inhibitors were taken at 72 hours.
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grem1 cells, while ALK3 and BMPRII expression levels 
did not change (Figure 7A). The small molecule ALK2/
ALK3 receptor inhibitor LDN193189 blocked BMP-2 
mediated induction of BMP-pathway activity in H2052 
cells (Figure 7B). Treatment of mesothelioma cells with 
LDN193189 for 3 days reduced BMP-pathway activity 
as expected, but did not induce TGF-β-pathway activity 
(Figure 7C). In agreement, BMP-pathway target gene ID1 
(inhibitor of DNA binding 1) mRNA was reduced, while 
SNAI2 and MMP2 expression remained unaltered after 
the inhibitor treatment (Figure 7D). Invasive growth of 
JP5/ctrl cells into Matrigel (Figure 7E) or collagen (data 
not shown) matrices was not enhanced by LDN193189 
treatment. These data indicate that gremlin-1 has a notable 
effect on the BMP signaling system in mesothelioma cells, 
but the inhibition of ALK2/ALK3 mediated BMP signals 
alone does not induce mesothelioma cell invasive growth.
JP5/grem1 xenograft tumors are more vascular 
and show a tendency to send metastasis
A pilot in vivo study was performed using orthotopic 
injection of JP5/ctrl and JP5/grem1 cells into the pleural 
cavity of nude mice. Tumor initiation and growth was 
slow, after 5 months follow up no visible tumors or 
luciferase signal were observed in JP5/ctrl cell injected 
Figure 5: TGF-β pathway activity contributes to gremlin-1 induced invasive growth. (A) Expression of TGF-β (TGFB1 and 
TGFB2) and activin-A (INHBA subunit) genes in gremlin-1 silenced (grem1_siRNA) H2052 or JL-1 cells and in JP5/grem1 cells. The 
results are expressed relative to each control (control siRNA transfected or JP5/ctrl), which was set to 1. The error bars represent SD (n = 
3). *p < 0.05. (B) BMP [(Bre)2-luc] and TGF-β [(CAGA)12-luc] pathway activities were analyzed using promoter reporter assays. Promoter 
activities in gremlin-1 siRNA (grem1_siRNA3) transfected H2052 cells or JP5/grem1 cells are shown relative to the levels in control 
siRNA (ctrl_siRNA) transfected or JP5/ctrl cells, respectively. The error bars represent SD (n = 3). *p < 0.05. (C) Secreted levels of active 
and total TGF-β were analyzed using TGF-β responsive reporter cells. The amount of cell conditioned media was normalized according to 
cell number. TGF-β levels in gremlin-1 silenced (grem1_siRNA) H2052 cells and JP5/grem1 cells are expressed relative to each control 
(control siRNA transfected or JP5/ctrl), which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (D) Invasive growth of H2052 
cells treated with a soluble inhibitor of activin signaling (sActR2B-Fc), recombinant follistatin or control inhibitor (sAMHR2-Fc, 0 h and 
72 h time points shown) was analyzed in 3D collagen 1 matrix. Cells were followed up to 72 hours.
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mice (Figure 8A). In JP5/grem1 cell injected mice 
formation of a few tumor nodules was observed in 2/4 
mice. Histologically the tumors showed epithelioid 
pattern and calretinin positivity, which is consistent with 
the original patient tumor type (Figure 8A–8B). In one 
JP5/grem1 tumor bearing mouse the adjacent lymph node 
was collected and stained for human calretinin. Isolated 
calretinin positive cells were detected suggesting that 
the tumor cells can travel to lymph nodes (Figure 8B). 
Isolated positive cells were also detected using the human 
lamin A+C antibody, confirming the human origin of the 
cells.
To enhance tumor initiation we next injected JP5/
ctrl and JP5/grem1 cells subcutaneously as Matrigel plugs 
into nude mice (n = 6, [17]). All mice developed tumors 
(Figure 8C–8D). In JP5/grem1 cell injected mice tumor 
development was delayed; however, the tumor growth 
in this group enhanced and at the time of sacrifice (2.5 
months) no difference in luciferase signal was observed. 
Proliferation marker protein Ki67 staining indicated no 
significant differences between JP5/ctrl and JP5/grem1 
tumors (Figure 8E–8F). In both groups, tumor cells were 
able to invade into the surrounding tissue as single cells 
or small colonies (Figure 8D). Although histologically 
the tumors did not differ notably, there was a tendency 
to form metastasis in JP5/grem1 tumor bearing mice. In 
2/6 JP5/grem1 mice but not in JP5/ctrl mice formation of 
metastasis was observed (Figure 8C).
Of note was the high vascularization of JP5/grem1 
tumors. The tumors contained visibly more blood vessels 
(Figure 9A). In agreement, staining of the tumor tissue 
with CD31 antibodies showed more staining and larger 
vessels in JP5/grem1 tumors (Figure 9B). Gremlin-1 
can signal through the VEGFR2 and it has also been 
recently linked to the regulation of VEGF expression in 
pigmentation epithelial cells [8, 18]. Notably, VEGFA 
mRNA expression was decreased in gremlin-1 silenced 
mesothelioma cells and increased in JP5/grem1 cells as 
compared to the controls (Figure 9C). Inhibition of TGF-β 
pathway activity with SB431542 did not alter VEGFA 
expression in JL-1 and JP5/grem1 cells. Gremlin-1 may 
thus have angiogenic functions either directly through 
Figure 6: TGF-β pathway receptor inhibitors reduce gremlin-1 induced 3D collagen invasion. (A) Invasive growth of 
H2052 and JP5/grem1 cells was analyzed in 3D collagen 1 matrix in the presence of DMSO or TGF-β/activin receptor inhibitors (SB431542 
or SB505124 at 10 μM concentration). Graphs show quantification as relative spheroid surface area. The error bars represent SD (n = 3). 
*p < 0.05. (B) Expression of PAI1, SNAI2, MMP2, MMP14 and ITGAV in SB431542 treated mesothelioma cells (JL-1 and JP5/grem1). 
The results are expressed relative to each control (DMSO treated cells), which was set to 1. The error bars represent SD (n = 3). *p < 0.05.
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VEGFR2 or by inducing VEGFA expression. Altogether, 
these data indicate that by inducing a mesenchymal 
invasive cell phenotype together with enhanced tumor 
vascularization, gremlin-1 drives mesothelioma invasion 
and metastasis.
DISCUSSION
Recently, gremlin-1 has emerged as a regulator 
of malignant cell behavior. Gremlin-1 can function as 
a niche factor modulating cell proliferation as well as 
regulates plasticity and stemness in cancer cells [7, 19, 
20]. In colorectal cancer, gremlin-1 has been localized to 
cancer invasive fronts in the tumor tissue [21]. In addition 
to inhibition of BMP-pathway activities, gremlin-1 can 
function through activation of VEGFR2 signaling and 
inhibition of MIF [8, 22]. Mesothelioma develops from 
mesothelial cells lining serosal membranes, most often 
from the pleura. Asbestos exposure is a causative factor 
in mesothelioma and we have previously shown that 
asbestos fibers can increase gremlin-1 expression in lung 
epithelial cells in vitro [23]. Normal mesothelial cells 
express low levels of gremlin-1, while non-malignant 
reactive pleural mesothelial cell already show activation 
of gremlin-1 expression [12]. Mesothelioma cells in 
tumor tissue display high gremlin-1 immunoreactivity in 
both epithelioid and sarcomatoid tumor areas. In addition, 
primary mesothelioma cells isolated from patient pleural 
fluids show high gremlin-1 expression. Gremlin-1 is 
targeted into fibrillin-2 containing microfibrils in the 
tumor microenvironment. Our present data suggest that 
gremlin-1 functions as an important regulator of the 
invasive growth behavior of mesothelioma cells in vitro 
and in vivo.
Figure 7: Inhibition of BMP receptor pathway alone does not induce invasive growth. (A) Expression of BMP-pathway genes 
in gremlin-1 silenced (grem1_siRNA) H2052 or JL-1 cells and in JP5/grem1 cells. The results are expressed relative to each control (control 
siRNA transfected or JP5/ctrl), which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (B) BMP [(Bre)2-luc] pathway activity 
was analyzed in H2052 cells using promoter reporter assays. Promoter activities in BMP-2 (25 ng/ml) and/or LDN193189 (100 nM) treated 
(24 hours) cells are shown relative to the level in control treated cells, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. 
(C) BMP [(Bre)2-luc] and TGF-β [(CAGA)12-luc] pathway activities were analyzed using promoter reporter assays. Promoter activities in 
LDN193189 (100 nM) treated cells (3 days) are shown relative to each control, which was set to 1. The error bars represent SD (n = 3). 
*p < 0.05. (D) Expression of ID1, SNAI2, and MMP2 in LDN193189 (100 nM) treated mesothelioma cells (H2052, JL-1 and JP5/ctrl). The 
results are expressed relative to each control, which was set to 1. The error bars represent SD (n = 3). *p < 0.05. (E) Control or LDN193189 
(100 nM) treated JP5/ctrl cells were embedded into 3D Matrigel and followed for 72 hours.
Oncotarget98290www.impactjournals.com/oncotarget
Figure 8: JP5/grem1 xenograft tumors show a tendency to send metastasis. (A) JP5/ctrl and JP5/grem1 mesothelioma cells 
transduced to express a luciferase marker gene were injected into the pleural cavity of nude mice and followed for 5 months (n = 4). 
Tumor nodules were analyzed by HE staining and human cells were identified with an antibody specific for human lamin A+C. (B) 
Immunohistochemical staining of JP5/grem1 tumor or an adjacent lymph node with an antibody specific to mesothelial marker calretinin. 
Inset: staining of the lymph node with lamin A+C antibody. (C) JP5/ctrl and JP5/grem1 mesothelioma cells transduced to express a luciferase 
marker were injected subcutaneously as Matrigel plugs. Tumor growth was followed by luciferase signal measurements for 2.5 months. The 
error bars represent SEM (n = 6). *p < 0.05. Formation of metastasis in JP5/grem1 mice is shown on the right. (D) Subcutaneous JP5/ctrl 
and JP5/grem1 tumors stained with an antibody specific to human lamin A+C. (E) Staining of tumors using Ki67 specific antibody. (F) The 
graph shows Ki67 positive staining area (%) in JP5/ctrl and JP5/grem1 tumors. The error bars represent SD (n = 6).
Oncotarget98291www.impactjournals.com/oncotarget
In some studies overexpression of gremlin-1 was 
found to induce proliferation in cultured epithelial or 
mesenchymal cells [24, 25]. Consistent with this, we 
observed previously that gremlin-1 silencing in H2052 
mesothelioma cells reduces proliferation [12]. However, 
primary mesothelioma cells tend to lose gremlin-1 
expression concomitantly with increased growth 
rate during passaging. In addition, in overexpression 
studies we have also observed reduced growth rate in 
gremlin-1 expressing cells. This may suggest that in 
cultured mesothelioma cells adapted to proliferate in 2D 
cultures the balance of gremlin-1 expression affects both 
proliferation and cell phenotype. Our data clearly suggest 
that gremlin-1 drives an EMT-phenotype in mesothelioma 
cells, which is often linked to reduced proliferative 
activity. This mesenchymal transition of mesothelial/
mesothelioma cells was strongly linked to invasive growth 
in 3D collagen matrix, mimicking somewhat better the 
tumor tissue microenvironment than 2D cultures. In vivo 
studies also suggested that in gremlin-1 overexpressing 
cells tumor development was slower, but there was a 
tendency to send metastasis. Gremlin-1 may thus play 
a role in mesothelioma cell invasion and dissemination 
rather than in the induction of high proliferative rate. The 
EMT transcription factor SNAI2 was previously shown to 
co-localize with gremlin-1 in mesothelioma tumor tissue 
and here we also observed that SNAI2 expression followed 
tightly gremlin-1 expression in cultured cells [12]. SNAI2 
has been linked to self-renewal capacity of cells as well 
as to the regulation of EMT processes [26, 27] and is 
likely an important mediator of gremlin-1 function in 
mesothelioma. In agreement with our data, a recent 
study identified gremlin-1 expression in effluent-derived 
mesothelial cells in peritoneal dialysis patients, which was 
associated with mesenchymal cell transition and peritoneal 
dysfunction [28].
Figure 9: JP5/grem1 tumors are more vascular. (A) Tumor blood vessels imaged by photography. (B) Staining of tumor blood 
vessels using mouse CD31 specific antibody. The graph shows CD31 positive staining area (%) in JP5/ctrl and JP5/grem1 tumors. The error 
bars represent SD (n = 6). *p < 0.05. (C) Expression of VEGFA gene in gremlin-1 silenced (grem1_siRNA) H2052 or JL-1 cells and in JP5/
grem1 cells. The results are expressed relative to each control (control siRNA transfected or JP5/ctrl), which was set to 1. The error bars 
represent SD (n = 3). *p < 0.05. (D) Expression of VEGFA in SB431542 treated mesothelioma cells (JL-1 and JP5/grem1). The results are 
expressed relative to each control (DMSO treated cells), which was set to 1. The error bars represent SD (n = 3). *p < 0.05.
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EMT is a developmental program that confers 
a mesenchymal phenotype to epithelial cells. Cancer 
cells show plasticity and can undergo mesenchymal 
transitions, characterized by changes in cell surface 
molecules, ECM proteins, matrix degrading enzymes 
and growth factor signaling [27]. We observed gremlin-1 
mediated alterations in integrin expression, especially 
the expression of integrin αv subunit (ITGAV) followed 
gremlin-1 levels. This integrin in complex with β3 integrin 
has been previously shown overexpressed in many types 
of cancers [29] and in mesothelioma it has been linked 
to cell attachment and invasion [30]. Cilengitide is an 
inhibitor of αvβ3 and αvβ5 integrins and was found to 
inhibit mesothelioma invasion in an agarose spot assay 
in this study. However, there was only a minor effect in 
invasion into 3D collagen, which is in agreement with 
our results. As cell culture models we used gremlin-1 
silencing in two different mesothelioma cell lines as well 
as gremlin-1 overexpression in low gremlin-1 expressing 
cells. Evidence from these models suggest that also MMP2 
and MMP14 expressions are regulated by gremlin-1. 
MMPs can break down ECM to allow cell migration 
as well as modulate the stroma to promote growth and 
invasion [31]. In agreement, inhibition of MMP activity 
prevented gremlin-1 induced mesothelioma cell invasion 
into 3D collagen.
TGF-β is a well-known regulator of EMT and 
involved in mesothelioma tumor biology. We have 
previously observed that by blocking BMP-pathway 
signaling, gremlin-1 can shift the balance towards 
increased TGF-β-pathway signaling [14]. There are also 
reports describing direct activation of the Smad-pathway 
by gremlin-1 [15]. In mesothelioma cells we observed 
gremlin-1 mediated regulation of the expression of the 
activin-A subunit (INHBA) as well as TGFB1 and TGFB2. 
Secretion of TGF-β activity and activation of promoter 
reporter activities were in agreement with the expression 
studies. We have previously linked activin signaling 
to mesothelioma invasive growth in 3D Matrigel [16]; 
however, inhibition of activin activity was not enough 
to reduced invasive growth in 3D collagen. A significant 
reduction was achieved when a small molecule inhibitor 
of TGF-β pathway receptors was used, evidence of the 
involvement of TGF-β/activin pathways in mesothelioma 
invasive growth. To get more insight into the importance 
of TGF-β pathway activity in gremlin-1 induced molecular 
changes, we analyzed mRNA expression after treatment 
of cells with the TGF-β receptor inhibitor. Interestingly, 
the expressions of MMP2 and PAI1, which is a known 
TGF-β target gene, was downregulated while SNAI2 and 
MMP14 expressions remained unchanged. These data 
suggest that activation of TGF-β pathway activity is only 
partially responsible for gremlin-1 mediated processes in 
mesothelioma cells.
Tumor xenograft studies are important to 
understand invasive growth of cancer cells in vivo. The 
in vivo tumorigenicity and growth of patient-derived 
mesothelioma xenografts in nude mice can vary a great 
deal [32, 33]. We observed slow growth and tumor 
development when using JP5 mesothelioma cells, 
gremlin-1 tumors taking more time to grow in the early 
phases of tumor development. Although the number 
of mice used in the studies was small, a clear tendency 
for gremlin-1 expressing mesothelioma cells to invade 
into lymph nodes and to metastasize was identified. In 
previous studies lymph node metastasis have also been 
noted in the later stages of xenograft growth in nude 
mice [32]. Gremlin-1 was also observed to be angiogenic, 
which is likely to contribute to the ability to form 
metastases from subcutaneous tumors. Hypoxia has been 
shown to induce gremlin-1 expression in the context of 
pulmonary hypertension [34]. In addition, gremlin-1 acts 
by binding and activating the VEGFR2 in endothelial 
cells to stimulate angiogenesis [8]. Here, we observed 
gremlin-1 mediated upregulation of VEGFA expression in 
mesothelioma cells. Angiogenesis is a prognostic factor in 
mesothelioma [35] and therapeutic interventions targeting 
angiogenic growth factor pathways have been tested in 
clinical trials. Addition of anti-VEGF antibody therapy 
to standard chemotherapy regimen was shown to offer a 
survival benefit of 2.7 months in a phase III clinical trial 
[36], while in another study small molecule inhibitor of 
VEGF receptors did not offer any clinical benefit [37, 38]. 
Mesothelioma tumors produce other angiogenic factors 
including FGFs, TGF-β and gremlin-1 [35] and further 
clinical studies are needed to assess the usefulness of anti-
angiogenic therapies in mesothelioma.
Gremlin-1 is consistently upregulated in 
mesothelioma [39] and drives a migratory and invasive 
mesenchymal phenotype. Mesenchymal transition is 
linked to chemoresistance and cancer prognosis [27]. 
Targeting gremlin-1 in mesothelioma tumor tissue may 
present a way to decrease chemoresistance and invasive 
growth by affecting multiple tumorigenic processes 
including mesenchymal programming and angiogenesis.
MATERIALS AND METHODS
Plasmids and siRNAs
Human gremlin-1 cDNA was amplified by 
polymerase chain reaction (PCR) using the following 
primers: 5′-CCGCTCGAGATGAGCCGCACAGCCTA 
CAC-3′ and 5′-GCTCTAGATTAATCCAAATCGATG 
GATATGC-3′ with XhoI and XbaI restriction sites, 
respectively. Gremlin-1 cDNA was then cloned into a 
lentiviral expression vector pLVX-puro (Clontech) and 
verified by DNA sequencing. Gremlin-1 is produced from 
this construct as a native protein without tags. LUC2 firefly 
luciferase gene (Promega) in pLVX-hygro vector was used 
as a reporter in in vivo studies. Gremlin-1 siRNAs and a 
negative control siRNA were from Life Technologies.
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Reagents and antibodies
Anti-gremlin-1 antibody was from Origene 
(TA324077), anti-E-cadherin antibody from BD 
Biosciences (610182) and anti-β-tubulin antibody from 
Santa Cruz (sc-9104). Integrin alpha v blocking antibody 
was from Millipore (MABT207) and used at 10 μg/ml 
concentration. Antibodies used for immunohistochemistry 
were anti-human calretinin (Abcam, ab16694), anti-
mouse CD31 (Abcam, ab124432), anti-Ki67 (Abcam, 
ab16667) and anti-human laminA+C nuclear envelope 
marker (Abcam, ab108595), which was used to identify 
human tumor cells in mouse tissue. Broad spectrum MMP 
inhibitors GM6001 and BB2516 were from Calbiochem 
and used at 10 μM concentration. TGF-βR inhibitors 
SB431542 and SB505124 were from Sigma-Aldrich and 
used at 10 μM concentration. BMP receptor inhibitor 
LDN193189 was from Sigma-Aldrich and used at 100 nM 
concentration. BMP-2 was from R&D Systems and used 
at 25 ng/ml concentration. The recombinant fusion protein 
containing the ectodomain of human ActR2B (sActR2B-
Fc) or anti-Müllerian hormone receptor (sAMHR2-Fc) 
fused to the Fc domain of human IgG1 and recombinant 
follistatin were produced as described previously [40] and 
used at 10 μg/ml. Soluble receptors sequester ligands and 
inhibit their binding to cell surface receptors.
Cell culture and transfections
Immortalized normal human mesothelial cells 
(Met5A) and human mesothelioma cell lines H2052, 
211H and H28 were from ATCC. JL-1 mesothelioma cell 
line was from DSMZ [41]. JP primary mesothelioma cells 
were acquired from pleural effusion samples from patients 
suffering from malignant mesothelioma as described [12]. 
Mesothelioma cells were cultured in RPMI-1640 medium 
(Sigma-Aldrich). 293FT cells (Invitrogen) were cultured 
in DMEM medium (Sigma-Aldrich) containing 4.5 μg/ml 
glucose. Culture media were supplemented with 10% heat-
inactivated fetal bovine serum (Thermo Fisher Scientific), 
1% L-glutamine, penicillin (100 U/ml), and streptomycin 
(100 µg/ml). Cells were incubated at 37°C in 5% CO2.
For plasmid and siRNA transfections, cells were 
detached with trypsin and seeded into plates to grow 
overnight in growth medium without antibiotics. A 
mixture of plasmid DNA or siRNA with Lipofectamine 
2000 transfection reagent (Invitrogen, Life Technologies) 
was added to the cells according to the manufacturer’s 
protocol. The medium was changed to normal growth 
medium 6 hours after transfection.
Lentivirus production and cell transduction
Lentiviruses were produced in 293FT cells using 
Lipofectamine 2000 (Invitrogen) transfection reagent. 
Supernatants of 293FT transfectants were collected 
48 hours after transfection and filtered using 0.45 µm 
filter units (Sartorius). JP5 cells were grown to 50–60% 
confluency and transduced with lentiviral particles in 
the presence of hexadimethrine bromide (10 µg/ml 
Polybrene, Sigma-Aldrich). Cells stably expressing firefly 
luciferase (LUC2) or human gremlin-1 were obtained by 
selection with hygromycin (200 µg/ml) or puromycine 
(20 µg/ml), respectively. Cells expressing LUC2 were 
further transduced with lentiviral particles containing 
either pLVX-puro empty vector or pLVX-puro carrying 
human gremlin-1. Western blotting against gremlin-1 was 
performed to assess the overexpression efficiency.
RNA isolation and quantitative RT-PCR
Total cellular RNA was isolated using RNeasy 
Mini kit (Qiagen) and reverse transcribed to cDNA using 
iScript cDNA synthesis Kit (Bio-Rad). The cDNAs 
were amplified using TaqMan Assays-on-Demand gene 
expression products (Applied Biosystems) and CFX96 
Real-time PCR detection system (Bio-Rad). The relative 
gene expression differences were calculated with the 
comparative ΔΔCT method and the results have been 
expressed as mRNA expression levels normalized to 
the levels of a gene with a constant expression (TBP, 
TATA-binding protein). Pathway-specific PCR array 
(extracellular matrix and adhesion, SABiosciences) was 
performed according to manufacturer’s instruction.
3D growth and invasion assays
Cell invasion assay in 3D Matrigel was performed 
as described [42]. Cells (2–4 × 103) were plated on 96-well 
plates pre-coated with 50 µl Matrigel (BD Biosciences, 
diluted 1:3 in serum-free culture medium), followed by 
another layer of Matrigel (45 µL) above the cells. Finally, 
normal cell growth medium containing 10% serum was 
added on top. Inhibitors were added into Matrigel and 
growth medium where indicated. The growth patterns and 
morphologies of the cells were followed and documented 
by microscopic photography using an AxioVert 200 
microscope (Carl Zeiss).
The 3D collagen invasion assay was performed as 
described [43]. Briefly, cell spheroids were obtained by 
overlaying cells in 0.5% agarose coated 96-well round 
bottom plate. Spheroids were then picked up, mixed with 
type I collagen (Sigma) and dropped on the surface of 
a culture plate. After collagen polymerization, normal 
growth medium was added. Growth and sprouting of cells 
from spheroids was monitored and photographed using 
AxioVert 200 microscope (Carl Zeiss). The spheroid 
surface area was determined using FijiImageJ 64 bit 
software by delineating the surrounding border of cell 
spheres with cellular protrusion and nodular extension in 
20 random images of three to six separate gels. Subsequent 
quantification of the delineated area was also performed 
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with the same software. Fold change was calculated by 
comparing the spheroid surface area to the surface area 
at time point zero, which was set to one. At least three 
independent experiments were performed.
Western blotting analysis
Western blot analyses of whole-cell protein lysates 
(RIPA lysis buffer supplemented with protease inhibitors, 
Thermo Fisher Scientific) and secreted proteins were 
performed as described [12]. Protein concentrations were 
assayed using a BCA protein assay Kit (Pierce, Rockfors, 
IL, USA). Equal amounts of protein were separated by 
SDS-PAGE using 4–20% gradient Tris-glycine gels 
(Bio-Rad) and transferred to nitrocellulose membranes 
(Bio-Rad). After incubation with primary and secondary 
antibodies, the proteins were detected using Odyssey 
imaging (Li-Cor Biosciences). Relative band densities 
were quantified using Image Studio Lite Ver 5.2 software 
(Li-Cor Biosciences).
Gelatin zymography
Concentrated cell conditioned medium (10×, 
Microcon concentrators, Millipore) was analyzed by 
gelatin zymography using precast 10% SDS-PAGE gels 
containing gelatin (Bio-Rad). The amount of media 
loaded into the gel was adjusted according to cell number, 
which was counted after the collection of the media. 
Conditioned medium from HT-1080 cells treated with 4 
nM PMA was used as a control. After electrophoresis the 
gels were processed and stained with Coomassie Brilliant 
Blue (Bio-Rad) as described [44]. Scanning of gels was 
performed using Epson Perfection 4490 Photo Scanner, 
and quantification using FijiImageJ 64 bit program.
Staining of F-actin
Cells were cultured on glass coverslips, fixed with 
3.5% (v/v) paraformaldehyde in PBS and permeabilized 
with 0.1% Triton X-100 in PBS. Filamentous actin was 
then stained with TRITC-conjugated phalloidin (Sigma-
Aldrich). The coverslips were mounted in Vectashield 
containing DAPI (Vector Laboratories). Fluorescent 
images were visualized and recorded using Zeiss Axio 
Imager.Z2 microscope (Carl Zeiss).
Cell adhesion assay
Cells were suspended in culture medium and plated 
into plasma fibronectin (pFN, 10 µg/mL in PBS, Sigma-
Aldrich) or collagen I (10 µg/mL in PBS, BD Bioscience) 
coated 96-well plates. Bovine serum albumin was used 
as a control. Cells were allowed to attach for 60 min at 
37°C, after which cell morphologies were documented 
with photography. Finally, the percentage of attached and 
spread cells was calculated. At least 100 cells in three 
randomly selected fields were analyzed.
Cell migration assays
The migratory capacity of JP5 cells was analyzed 
using Incucyte ZOOM 2013A kinetic live cell imaging 
system (Essen Bioscience). The cells were plated on 96-
well plates and the next day a wound was applied using 
a wound maker (Essen Bioscience). The media was 
replaced with serum-free media. Two distinct pictures 
were taken of each well every 2 hours for 24 hours. Data 
were analyzed with Incucyte ZOOM 2013A software and 
the relative wound density was used as a measure of the 
wound closure.
Transwell cell migration/invasion assays were 
performed as described previously [42]. The inserts 
(8 μm pores, Corning Costar) were coated on the outer 
surface with collagen-I (45 μg/ml, BD Bioscience) and 
the lower chamber was filled with serum-free medium. 
Alternatively, the inserts were used without coating and 
the lower chamber was filled with medium containing 1% 
serum as chemoattractant. Cells (1–2 × 104) in serum-free 
medium were then added to the upper chamber. After an 
18-hour incubation the insert filters were fixed in 3.5% 
paraformaldehyde and stained with 0.5% crystal violet (in 
20% methanol). Cells on the upper side of the filter were 
scraped off, and migrated cells on the lower side were 
photographed and counted. Experiments were repeated at 
least three.
TGF-β/BMP luciferase reporter assays
Cells to be transfected were seeded in 96-well plates. 
The cells were co-transfected with promoter constructs 
(CAGA)12-luc (Smad3 responsive) or (Bre)2-luc (Smad1/5 
responsive), kindly provided by Dr. Peter ten Dijke 
(Leiden University Medical Center, the Netherlands), 
together with pRL-TK (Renilla luciferase control, 
Promega) plasmid using Fugene HD transfection reagent 
(Roche). After a three-day incubation, the cells were 
lysed and subjected to luciferase activity measurement by 
Dual Luciferase Reporter Assay (Promoga) and DCR-1 
luminometer (MGM Instruments Digene Diagnostics Inc.). 
The luciferase activities were normalized to constitutively 
expressed Renilla luciferase activities, and the results are 
expressed relative to control.
TGF-β activity assay
Mink lung epithelial cells stably transfected with a 
fragment of the human plasminogen activator inhibitor-1 
promoter fused to the firefly luciferase reporter gene 
(TMLC) were kindly provided by Dr. Daniel Rifkin (NYU 
School of Medicine, New York). The cells respond to TGF-β 
with luciferase activity and were used to assess the amount 
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of active and total TGF-β present in the cell conditioned 
media. For measurement of total TGF-β activity, heat 
treatment (80°C, 5 min) was used to activate latent forms 
of TGF-β. Analysis of TGF-β in standards and medium 
samples was performed as described [45]. The results have 
been presented as relative values of TGF-β activity.
Orthotopic pleural xenografts and subcutaneous 
xenografts
All experiments involving animals were approved 
by the Provincial State Office of Southern Finland 
(ESAVI/2083/04.10.07/2015) and carried out in 
accordance with institutional guidelines, which fulfill 
the requirements defined in regulations of the Finnish 
Act on the Protection of Animals used for Scientific or 
Educational Purposes (497/2013) and were performed 
according to the 3R. Female 6-week-old Balb/c nu/nu 
mice (Scanbur) were used. Orthotopic pleural xenograft 
model was applied to mimic the human mesothelioma 
microenvironment. JP5 cells (1 × 106) expressing 
firefly luciferase together with human gremlin-1 (JP5/
grem1) or control vector (JP5/ctrl) were directly injected 
into the pleural cavity through the intercostal space. 
Subcutaneous xenografts were performed by injecting 
JP5 cells (1 × 106) mixed with Matrigel Matrix (BD 
Biosciences, final concentration 7 mg/ml) into the flank 
region of mice. The procedures were performed under 
isoflurane anesthesia and the mice were observed until 
recovery. Successful injection of tumor cells as well as 
tumor growth was followed by bioluminescence imaging. 
D-Luciferin (Regis Technologies) in PBS was injected 
intraperitoneally and allowed to circulate for 10 min. 
Emitted photons were monitored with IVIS Kinetic whole 
animal imaging system (Perkin-Elmer). The weight of 
mice was monitored regularly throughout the experiments. 
Tumor tissue of sacrificed mice was collected, fixed in 4% 
paraformaldehyde, dehydrated and embedded in paraffin.
Immunohistochemistry
Paraffin-embedded tissue samples were processed 
and stained using the Leica BOND-MAX fully automated 
staining system (Leica Bond Polymer Refine Detection-
kit and Bond Epitope Retrieval Solution 1, 20 mins). 
The primary antibody incubation was 60 min. Negative 
control sections were incubated with rabbit isotype 
control (Invitrogen). The slides were scanned digitally 
(Pannoramic FLASH II, 3DHistech) and analyzed using 
CaseViewer program and HistoQuant quantification 
module (3DHistech).
Statistical analyses
All comparisons were made using nonparametric 
tests with SPSS version 24 software (IBM). Two-group 
comparisons were made using Mann-Whitney U-test. P 
values below 0.05 were considered statistically significant.
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